- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05133492
First In Human Study for Small to Medium-sized Abdominal Aortic Aneurysm (AAA) (AAA)
January 2, 2024 updated by: Nectero Medical, Inc.
A Clinical Pilot Study to Evaluate the Safety and Clinical Utility of The Nectero EAST System for Stabilization of Abdominal Aortic Aneurysms
This is a first in human study to evaluate the safety and clinical utility of an investigational medical device called the Nectero EAST System to treat Abdominal Aortic Aneurysms or AAA.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Detailed Description
This is a Phase I multi-center, open-label study to evaluate use of the Nectero EAST system for stabilization of abdominal aortic aneurysms. Up to fifty (50) subjects will be treated at up to 10 worldwide sites with the device and followed for up to 36-months.
Primary Study Endpoints:
- Safety: absence of major events within the 1-month follow-up visit
- Success: defined as successful insertion of the delivery catheter and delivery of the Stabilizer
Secondary Study Endpoints:
- Freedom from aneurysmal sac enlargement. Enlargement is defined as diameter increase of >5mm per year, or aneurysm sac volume increase of >10% per year, as assessed by CT scans at the 1, 3, (HK only), 6, 12, 24 and 36-month follow-up visits.
- Aneurysm sac shrinkage, defined as diameter decrease of >5mm, or decrease in aneurysm sac volume of >10% as assessed by CT scans at the 1, 3 (HK only), 6, 12, 24 and 36-month follow-up visits.
- Assessment of Clinical Utility
Study duration is anticipated to be 6 years.
Study Type
Interventional
Enrollment (Actual)
46
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Charlene Knape
- Phone Number: (866) 755-4744
- Email: cknape@necteromedical.com
Study Contact Backup
- Name: Kelvin Ning
- Phone Number: (866) 755-4744
- Email: kning@necteromedical.com
Study Locations
-
-
New South Wales
-
Randwick, New South Wales, Australia, 2031
- Prince of Wales Private Hospital
-
-
-
-
Southern District
-
Hong Kong, Southern District, China
- Queen Mary Hospital
-
-
-
-
Antioquia
-
Medellín, Antioquia, Colombia
- Pablo Tabon Uribe Hospital
-
-
-
-
-
Auckland, New Zealand
- Auckland City Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Male or Female aged 18 years or older
- Subject can understand the purpose of the trial, voluntarily participate in the trial and sign the informed consent and is willing to complete the follow-up according to the requirements of the protocol.
- Infrarenal non-aneurysmal neck ≥15mm in length
- Aortic neck diameters ≤ 29mm
- Infrarenal neck angulation ≤ 60°
- Abdominal aneurysm from 3.5 cm to 5.0 cm.
- Overall AAA treatment length (distal renal to distal inferior margin of the aneurysm) not to exceed 10 cm
- Patient iliac or femoral arteries access vessels' size and morphology allow endovascular access of 14F introducer sheaths and catheters.
- Subject has > one-year life expectancy.
- Subject is American Society of Anesthesiology (ASA) grade 1 through 3, inclusive.
- Subject is able and willing to comply with 1, 3, 6, 12, 24 and 36-month follow-up.
Exclusion Criteria:
- Subject has an acutely ruptured or leaking or emergent aneurysm.
- Subject has a dissecting aneurysm.
- Subject has a mycotic or infected aneurysm.
- Subject has current vascular injury due to trauma.
- Subject's aneurysm is thoracic or suprarenal.
- Previous surgical or endovascular aneurysm repair for abdominal aortic aneurysm.
- Subject has thrombus, calcification, and/or plaque that may compromise delivery.
- Subject has had a myocardial infarction within six (6) months prior to enrollment.
- Subject has current angina or other active cardiac condition such as congestive heart failure, untreated or worsening atrial arrhythmia, ventricular arrhythmia, or valvular disease.
- Subject has undergone other major surgery within the 30 days prior to enrollment.
- Subjects with any transient ischemic attack (TIA) or ischemic stroke within 3 months.
- Known allergy to polyester or contrast material that cannot be pretreated.
- Subject is morbidly obese or has other clinical conditions that severely inhibit X-ray visualization of the aorta.
- Subject has connective tissue disease (e.g., Marfan syndrome, Eaton syndrome, or Bessel's disease).
- Known contraindication to undergoing angiography or anticoagulation.
- Subject has active systemic infection.
- Subject is participating in another research study.
- Subject has other medical, social, or psychological problems that, in the opinion of the investigator, preclude them from receiving this treatment and the procedures and evaluations pre- and post-treatment.
- Women of childbearing potential who are pregnant, lactating, or planning to become pregnant during the course of the trial.
- Subject has dialysis dependent renal failure or baseline serum creatinine level >2.0mg/dl.
- Subjects with liver dysfunction: alanine transaminase (ALT) or aspartate transaminase (AST) is five times higher than the normal upper limit; serum total bilirubin (STB) is two times higher than the normal upper limit.
- Subjects who are not suitable for endovascular treatment, as judged by the investigator.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Interventional
Use of the EAST System for the stabilization treatment of AAA.
The device is delivered endovascularly and placed in the AAA sac to deliver the Stabilizer Infusion Solution.
|
Endovascular procedure: an ipsilateral ilio-femoral aortogram to confirm suitability for placement of a 14F sheath will be performed.
A baseline contrast aortogram will be performed to assess vessel patency and target location of the EAST delivery catheter.
Occluding and Stabilizer balloons are inflated in preparation for Stabilizer Compound delivery within the AAA sac.
A post-Stabilizer angiogram will re-assess vessel patency and aorta stability.
Delivery catheter is removed and discarded.
The entire procedure is approximately one hour.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety: Procedure and Device-Related Adverse Events
Time Frame: Up to 30 days
|
Absence of major events (procedure and device-related) within the 1-month follow-up visit
|
Up to 30 days
|
Efficacy: Successful delivery of the EAST System into the AAA sac
Time Frame: Up to 30 days
|
Successful insertion of the delivery catheter and delivery of the Stabilizer Compound
|
Up to 30 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Efficacy: Evaluation of the AAA sac diameter over the 36 month follow up period.
Time Frame: Through study completion, an average of 3 years
|
Freedom from aneurysmal sac enlargement.
Enlargement is defined as diameter increase of >5mm per year, or aneurysm sac volume increase of >10% per year, as assessed by CT scans at the 1, 3, (HK only), 6, 12, 24 and 36-month follow-up visits.
|
Through study completion, an average of 3 years
|
Efficacy: Evaluation of the AAA sac shrinkage over the 36 month follow up period.
Time Frame: Through study completion, an average of 3 years
|
Aneurysm sac shrinkage, defined as diameter decrease of >5mm, or decrease in aneurysm sac volume of >10% as assessed by CT scans at the 1, 3 (HK only), 6, 12, 24 and 36-month follow-up visits.
|
Through study completion, an average of 3 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Stephen Cheng, MD, Queen Mary Hospital, Hong Kong
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 24, 2019
Primary Completion (Estimated)
December 31, 2026
Study Completion (Estimated)
December 31, 2026
Study Registration Dates
First Submitted
November 3, 2021
First Submitted That Met QC Criteria
November 12, 2021
First Posted (Actual)
November 24, 2021
Study Record Updates
Last Update Posted (Actual)
January 5, 2024
Last Update Submitted That Met QC Criteria
January 2, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CTP001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Abdominal Aortic Aneurysm
-
Assistance Publique - Hôpitaux de ParisUnknownSmall Abdominal Aortic Aneurysm | Abdominal Aortic Aneurysm,France
-
Karolinska University HospitalEnrolling by invitationAneurysm | Aortic Aneurysm | Abdominal Aortic Aneurysm, Ruptured | Aneurysm Abdominal | Abdominal Aortic Aneurysm Without RuptureSweden
-
EndologixActive, not recruiting1 Paravisceral Abdominal Aortic Aneurysm | 2 Juxtarenal Abdominal Aortic Aneurysm | 3 Pararenal Abdominal Aortic Aneurysm | 4 Complex Abdominal Aortic AneurysmsUnited States
-
Medtronic CardiovascularCompletedAbdominal Aortic Aneurysms (AAA)United States
-
Vascutek Ltd.TerminatedAbdominal Aortic Aneurysms (AAA)United Kingdom, Netherlands, Switzerland, Spain, Germany, Belgium, Sweden, Canada, France, Italy, Austria, Monaco
-
Timothy Chuter, MDRecruitingThoracoabdominal Aortic Aneurysm | Paravisceral Abdominal Aortic AneurysmUnited States
-
Washington University School of MedicineRecruitingAbdominal Aortic Aneurysm (AAA) | No Abdominal Aortic Aneurysm (Non-AAA)United States
-
University of California, San DiegoRecruitingJuxtarenal Aortic Aneurysm | Thoracoabdominal Aortic Aneurysm | Pararenal Aortic Aneurysm | Complex Abdominal Aortic AneurysmUnited States
-
Assistance Publique Hopitaux De MarseilleCompletedAbdominal Aortic AneurysmsFrance
-
Hangzhou Endonom Medtech Co., Ltd.RecruitingJuxtarenal Abdominal Aortic AneurysmChina
Clinical Trials on Endovascular Aneurysm Stabilization Treatment (EAST)
-
CHU de ReimsCompletedIntracranial AneurysmFrance
-
Balt InternationalUnknownIntracranial AneurysmsGermany
-
Phenox GmbHUnknownIntracranial Aneurysm
-
Darren Schneider, M.D.RecruitingEndovascular Treatment of TAAA and Aortic Arch Aneurysms Using Fenestrated and Branched Stent GraftsAortic Aneurysm, Thoracic | Aortic Aneurysm, Thoracoabdominal | Aortic Dissection, ThoracoabdominalUnited States
-
Karolinska University HospitalRecruitingQuality of Life | Aortic Aneurysm, Abdominal | Aortic AneurysmSweden
-
Medtronic CardiovascularCompletedAbdominal Aortic AneurysmsUnited States
-
Sohag UniversityRecruitingWide Neck Saccular Cerebral AneurysmsEgypt
-
Medical University of ViennaJohannes Kepler University of LinzUnknown
-
University of North Carolina, Chapel HillCook Group Incorporated; UNC HospitalsEnrolling by invitationAortic Aneurysm, Abdominal | Aortic Arch Aneurysm | Ascending Aorta AneurysmUnited States
-
JOTEC GmbHActive, not recruiting